HRP20080495T3 - 8-hidroksi-5-/(-hidroksi-2-//(1r)-2-(4-metoksifenil)-1-metiletil/amino//ethil-2(1h)-kinolinon monohidroklorid u kristaličnom obliku i postupak njihove priprave - Google Patents

8-hidroksi-5-/(-hidroksi-2-//(1r)-2-(4-metoksifenil)-1-metiletil/amino//ethil-2(1h)-kinolinon monohidroklorid u kristaličnom obliku i postupak njihove priprave

Info

Publication number
HRP20080495T3
HRP20080495T3 HR20080495T HRP20080495T HRP20080495T3 HR P20080495 T3 HRP20080495 T3 HR P20080495T3 HR 20080495 T HR20080495 T HR 20080495T HR P20080495 T HRP20080495 T HR P20080495T HR P20080495 T3 HRP20080495 T3 HR P20080495T3
Authority
HR
Croatia
Prior art keywords
hydroxy
methylethyl
methoxyphenyl
ethyl
amino
Prior art date
Application number
HR20080495T
Other languages
English (en)
Inventor
Pivetti Fausto
Pighi Roberto
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20080495(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of HRP20080495T3 publication Critical patent/HRP20080495T3/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Postupak priprave 8-hidroksi-5-[(1R)-1-hidroksi-2-([(1R)-2-(4-metoksifenil)-1-metiletil]-amino]-etii]-2(1H)-kinolinon monohidroklorida (I), naznačen time da obuhvaća kristalizaciju i prekristalizaciju spoja (I) iz smjese etanol-voda u omjeru od 97:3do 95:5 uz dodatak diizopropil-etera, pri čemu sesmjesa etanol-voda uparava pod sniženim tlakom pri temperaturi između 30 i 55 °C na volumen koji jeizmeđu 1/2 i 1/3 početnog volumena, a diizopropil-eter se dodaje tijekom najmanje 5 minuta. Patent sadrži još 5 patentnih zahtjeva.
HR20080495T 2004-03-24 2008-10-01 8-hidroksi-5-/(-hidroksi-2-//(1r)-2-(4-metoksifenil)-1-metiletil/amino//ethil-2(1h)-kinolinon monohidroklorid u kristaličnom obliku i postupak njihove priprave HRP20080495T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007045 2004-03-24
PCT/EP2005/003144 WO2005089760A1 (en) 2004-03-24 2005-03-24 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl] -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation

Publications (1)

Publication Number Publication Date
HRP20080495T3 true HRP20080495T3 (hr) 2008-11-30

Family

ID=34963779

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080495T HRP20080495T3 (hr) 2004-03-24 2008-10-01 8-hidroksi-5-/(-hidroksi-2-//(1r)-2-(4-metoksifenil)-1-metiletil/amino//ethil-2(1h)-kinolinon monohidroklorid u kristaličnom obliku i postupak njihove priprave

Country Status (30)

Country Link
US (1) US20070197586A1 (hr)
EP (1) EP1729773B1 (hr)
JP (1) JP2007530489A (hr)
KR (1) KR20070001946A (hr)
CN (2) CN1929840B (hr)
AR (1) AR048339A1 (hr)
AT (1) ATE399552T1 (hr)
AU (1) AU2005224032A1 (hr)
BR (1) BRPI0508213A (hr)
CA (1) CA2560650A1 (hr)
CY (1) CY1108323T1 (hr)
DE (1) DE602005007871D1 (hr)
DK (1) DK1729773T3 (hr)
EA (1) EA010128B1 (hr)
ES (1) ES2309739T3 (hr)
HR (1) HRP20080495T3 (hr)
IL (1) IL178227A0 (hr)
MA (1) MA28549B1 (hr)
MX (1) MXPA06010515A (hr)
NO (1) NO20064274L (hr)
NZ (1) NZ550010A (hr)
PE (1) PE20060159A1 (hr)
PL (1) PL1729773T3 (hr)
PT (1) PT1729773E (hr)
RS (1) RS50602B (hr)
SI (1) SI1729773T1 (hr)
TN (1) TNSN06249A1 (hr)
UA (1) UA86221C2 (hr)
WO (1) WO2005089760A1 (hr)
ZA (1) ZA200607907B (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CA2534693A1 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride

Also Published As

Publication number Publication date
SI1729773T1 (sl) 2008-10-31
ZA200607907B (en) 2008-04-30
AU2005224032A1 (en) 2005-09-29
MA28549B1 (fr) 2007-04-03
UA86221C2 (en) 2009-04-10
EP1729773A1 (en) 2006-12-13
CA2560650A1 (en) 2005-09-29
CN1929840A (zh) 2007-03-14
BRPI0508213A (pt) 2007-07-17
PE20060159A1 (es) 2006-04-04
TNSN06249A1 (en) 2007-12-03
MXPA06010515A (es) 2007-03-30
RS50602B (sr) 2010-05-07
EA010128B1 (ru) 2008-06-30
DE602005007871D1 (de) 2008-08-14
ATE399552T1 (de) 2008-07-15
US20070197586A1 (en) 2007-08-23
NO20064274L (no) 2006-10-13
AR048339A1 (es) 2006-04-19
WO2005089760A1 (en) 2005-09-29
EA200601531A1 (ru) 2007-04-27
CN1929840B (zh) 2010-12-08
CN101812017A (zh) 2010-08-25
CY1108323T1 (el) 2014-02-12
PT1729773E (pt) 2008-09-29
EP1729773B1 (en) 2008-07-02
PL1729773T3 (pl) 2008-12-31
IL178227A0 (en) 2006-12-31
KR20070001946A (ko) 2007-01-04
JP2007530489A (ja) 2007-11-01
ES2309739T3 (es) 2008-12-16
DK1729773T3 (da) 2008-10-20
NZ550010A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
HRP20080495T3 (hr) 8-hidroksi-5-/(-hidroksi-2-//(1r)-2-(4-metoksifenil)-1-metiletil/amino//ethil-2(1h)-kinolinon monohidroklorid u kristaličnom obliku i postupak njihove priprave
CA2936408C (en) Triazine compounds and pharmaceutical use thereof
TW201100393A (en) Substituted aminobutyric derivatives as neprilysin inhibitors
AR029857A1 (es) Derivados de acidos sulfonil-amino-metil-benzoicos sustituidos y procedimiento para su preparacion
EA200800142A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, СОДЕРЖАЩИЕ β-АГОНИСТ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ, ДЛЯ ВВЕДЕНИЯ ПУТЕМ РАСПЫЛЕНИЯ
WO2021111179A8 (en) Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
EA200601578A1 (ru) Стабильные фармацевтические растворы для дозированных ингаляторов под давлением
JP2015531376A5 (hr)
EA200400311A1 (ru) Кристаллы производных гидроксинорэфедрина
HRP20090236T1 (hr) DERIVATI PIRIDO[2,3-d]PIRIMIDINA, NJIHOVO DOBIVANJE I TERAPIJSKA PRIMJENA
WO2010128355A3 (en) Improved processes for preparing substantially pure arformoterol and its intermediates
US20200255422A1 (en) Inhibitors of trim33 and methods of use
DK180408B1 (en) Dihydroisoxazole compound for use in controlling sea lice
MX2021009796A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
BR112014028362A2 (pt) Ácidos (3r, 4r, 5s)-5-guanidino-4acetamido-3-(pentan- 3iloxi)cicloexeno-1-carboxílicos flúor substituídos, os seus ésteres e uso dos mesmos
US11116736B2 (en) 2-amino-N'-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases
WO2021055797A9 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
PE20230347A1 (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparacion y uso
WO2021044230A8 (en) Process for the synthesis of the sodium salt of 4-[[(lr)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2h)-pyrimidinyl]-1- phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process
WO2009109973A2 (en) Compounds and methods of treating obesity
WO2013162298A1 (ko) 신규한 베타 알라닌 유도체, 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 약제학적 조성물
CA3154064A1 (en) The salts of a compound and the crystalline forms thereof
IL211747A (en) Reliable aryl sulfonamide compounds and their use as 5–6ht ligands
WO2007085933A3 (en) Process for the preparation of n-[1-(s)-ethoxycarbonyl-1-butyl]-(s)-alanine-dmt complex and its use in the preparation of perindopril
DK1791808T3 (da) Fremgangsmåde til fremstilling af 4,5-diaminoshikiminsyre